Novadaq: study shows FVT, ICG plus Opttx System effective in wet AMD

By Lisa Kerner

Charlotte, N.C., Sept. 11 - Novadaq Technologies Inc. said results of a 40-patient clinical trial showed conventional feeder vessel therapy (FVT) with indocyanine green (ICG) was more effective than FVT alone in patients with wet age-related macular degeneration (AMD).

Both treatment groups were also treated with Novadaq's proprietary Opttx System imaging device.

In addition, the amount of energy needed to close abnormal vessels, a manifestation of wet AMD, was seven times less per treatment in the ICG arm than the conventional FVT arm.

The 12-month follow-up study met its primary objective and endpoint, according to the Toronto-based medical device company.

The results were presented at the joint American Society of Retinal Specialists, European Vitreo Retinal Society meeting in Cannes, France.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.